CRIO’s chief innovation officer, Mike Wenger touches on the two ways sites get AI adoption wrong.
|Articles|December 1, 2015
- Applied Clinical Trials-12-01-2015
- Volume 24
- Issue 12
Applied Clinical Trials Digital Edition - December 2015/January 2016
Regulatory: Assessing Study Drop in CEE Swiss Syncs Up Regulations Sites: Regional Risks in Eastern Europe Also in this issue: Orphan Drug Hurdles in Europe Patient Engagement: Illness-Level Impact Clinical Trial Technology in 2025
Advertisement
Articles in this issue
almost 11 years ago
Orphans of the Stormalmost 11 years ago
Technology-Driven R&D to be Prime Topic at DIA’s EuroMeetingalmost 11 years ago
How Will Technology Drive Global Clinical Trial Change by 2025?almost 11 years ago
New EU Trials Law: Headway, Concernsalmost 11 years ago
Switzerland Guides Innovation in Clinical Trial Regulationsalmost 11 years ago
Decline of Trials in CEE: Fluctuation or Trend?almost 11 years ago
Site Challenges in Eastern Europealmost 11 years ago
Rethinking Patient Engagement: Mild vs. Severe Illnessalmost 11 years ago
Patients, PDUFA, Pandemics to Shape R&D in 2016almost 11 years ago
Applied Clinical Trials, December 2015/January 2016 Issue (PDF)Advertisement
Related to this article
CRIO’s Mike Wenger, speaker at this year's SCRS summit, maps how sites are actually deploying AI post-pilot stage.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening the distance between signals, human judgment, and the next best action.
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Paradigm’s Kurt Mussina touches on why he rejects the “site management organization” model in favor of one unified business.
ProofPilot’s Lauren Briggs talks on why sponsors and CROs fail at tech rollouts by skipping change management, and pushes for the industry to judge trial technology by real workflow impact rather than feature checklists.
ProofPilot’s Lauren Briggs touches on why site tech adoption hinges on the first 90 days after rollout, and why tools succeed only when they remove work from a site’s plate rather than adding another login to juggle.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How Compressing Time From Data Capture to Insight Changes Trial Risk Management
2
What It Actually Means to Embed AI Across the Clinical Operating Model
3
2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?
4
2026 SCRS Global Site Solutions Summit: What's the Biggest Mistake Sites or Sponsors Make When Implementing Advanced Al?
5